{"meta":{"query_hash":"6527942ba211","filters":{"venue":"Journal of health economics and outcomes research"},"cohort_total":32,"direct_labels_cover":0,"predictions_cover":32,"exported":32,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/6527942ba211","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+health+economics+and+outcomes+research"},"results":[{"id":"W2346554787","doi":"10.36469/9831","title":"How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines","year":2015,"lang":"en","type":"review","venue":"Journal of health economics and outcomes research","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Type 2 diabetes; Excellence; Markov model; Psychological intervention; Cohort; Nice; Computer science; Gerontology; Diabetes mellitus; Markov chain; Machine learning","score_opus":0.7979155451812675,"score_gpt":0.5938924688310505,"score_spread":0.204023076350217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346554787","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018513088,0.99000496,0.0015012486,0.0064426186,0.00046102525,0.00007840976,0.00029753058,0.00002121151,0.0010079329],"genre_scores_gemma":[0.006543155,0.9840306,0.005370196,0.002795113,0.00045960426,0.00030869967,0.0003115784,0.000024864577,0.00015613495],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.97445333,0.013740185,0.0059425477,0.0010904416,0.0043547507,0.0004186842],"domain_scores_gemma":[0.8993587,0.08627399,0.0057088584,0.0011438018,0.0069926647,0.0005220847],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.038517125,0.002626038,0.006505231,0.016753945,0.00070550543,0.006432258,0.0052411407,0.004191184,0.0038771457],"category_scores_gemma":[0.1422026,0.0019333205,0.008996217,0.01590313,0.0014212406,0.0063952105,0.0020812636,0.0057425504,0.00082013686],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037905126,0.00013935848,0.0024162787,0.18936734,0.0044569415,0.0001376279,0.00039166625,0.009072746,0.00006055151,0.06117557,0.090562604,0.6418404],"study_design_scores_gemma":[0.00031100705,0.00015643101,0.0033857275,0.57456297,0.0064754933,0.00044352058,0.0003620422,0.0065204343,0.00019626123,0.071539044,0.33586118,0.00018595166],"about_ca_topic_score_codex":0.014207172,"about_ca_topic_score_gemma":0.010949638,"teacher_disagreement_score":0.9614829,"about_ca_system_score_codex":0.012404867,"about_ca_system_score_gemma":0.011140483,"threshold_uncertainty_score":0.20370048},"labels":[],"label_agreement":null},{"id":"W2580974718","doi":"10.36469/9818","title":"What Drives Responses to Willingness-to-pay Questions? A Methodological Inquiry in the Context of Hypertension Self-management","year":2016,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Descriptive statistics; Willingness to pay; Actuarial science; Valuation (finance); Test (biology); Context (archaeology); Psychological intervention; Multivariate statistics; Contingent valuation; Medicine; Psychology; Statistics; Economics; Nursing; Accounting; Mathematics","score_opus":0.7052211355047316,"score_gpt":0.5771883943140663,"score_spread":0.12803274119066532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2580974718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9000919,0.0029300533,0.06011847,0.01873878,0.0002703879,0.004554618,0.00040955967,0.000037366215,0.012848766],"genre_scores_gemma":[0.98012996,0.0003346682,0.01405814,0.0017353849,0.000051327388,0.0033036175,0.0000855967,0.000018327262,0.00028295183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.45098796,0.505342,0.017592564,0.008756233,0.013576031,0.0037451265],"domain_scores_gemma":[0.2304935,0.7190281,0.02858453,0.00929428,0.011328616,0.0012709069],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.38674036,0.0005379128,0.0014319664,0.0044545904,0.0030734085,0.009699257,0.0028626292,0.0036116417,0.004599506],"category_scores_gemma":[0.65394545,0.00092553697,0.0026005495,0.005264399,0.009222684,0.0065890756,0.0043699355,0.0030124334,0.0003920231],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011679925,0.0013945346,0.4379271,0.0063114315,0.0018596373,0.000591034,0.35072666,0.0021133148,0.00074094854,0.05816357,0.0026422625,0.13636152],"study_design_scores_gemma":[0.0006499117,0.0024456591,0.34277126,0.0070637832,0.0010843319,0.0009772417,0.47628555,0.021004828,0.0013875781,0.12780456,0.018134639,0.0003907498],"about_ca_topic_score_codex":0.0036596952,"about_ca_topic_score_gemma":0.002917654,"teacher_disagreement_score":0.6132597,"about_ca_system_score_codex":0.0072636646,"about_ca_system_score_gemma":0.0073510194,"threshold_uncertainty_score":0.75625837},"labels":[],"label_agreement":null},{"id":"W2785965739","doi":"10.36469/9817","title":"Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States","year":2016,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"LEO Pharma; Astellas Pharma; Mylan; Celgene; Eli Lilly and Company; Valeant Pharmaceuticals International; Pfizer; National Psoriasis Foundation","keywords":"Psoriasis; Tolerability; Medicine; Adverse effect; Logistic regression; Preference; Quality of life (healthcare); Internal medicine; Physical therapy; Statistics; Dermatology","score_opus":0.07272751935305925,"score_gpt":0.3735386163132736,"score_spread":0.30081109696021435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785965739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992454,0.000107650245,0.00005417978,0.00010177726,0.000002195824,0.0000048658862,0.000033362456,7.733912e-7,0.00044988512],"genre_scores_gemma":[0.9998342,0.00003161429,0.000045909994,0.000038068527,0.0000019843667,0.0000024231488,0.000016796246,3.4525138e-7,0.000028663704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983998,0.0010955936,0.00010630766,0.000092321636,0.00020799604,0.0000979794],"domain_scores_gemma":[0.9942246,0.003212429,0.001814851,0.00013102303,0.00023188723,0.0003850867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024855374,0.00013101257,0.00019059952,0.00037562658,0.00025317835,0.0006063444,0.00011238768,0.00040569904,0.0023168405],"category_scores_gemma":[0.00736434,0.000110693276,0.00039868447,0.00035304727,0.00030945567,0.0003076976,0.00029522524,0.0005415822,0.00013483042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012570096,0.00022632325,0.98091817,0.00003780225,0.00013329522,0.000102292346,0.000742895,0.00038478398,0.0006774104,0.00012764844,0.00034140045,0.015050952],"study_design_scores_gemma":[0.000101253405,0.00069469534,0.9926092,0.00004008866,0.00009593603,0.0006508392,0.0021531628,0.002401319,0.00028148515,0.00030241397,0.00064734934,0.00002220749],"about_ca_topic_score_codex":0.0019002913,"about_ca_topic_score_gemma":0.0029863138,"teacher_disagreement_score":0.0024855374,"about_ca_system_score_codex":0.00034568598,"about_ca_system_score_gemma":0.000225191,"threshold_uncertainty_score":0.01314497},"labels":[],"label_agreement":null},{"id":"W2975211644","doi":"10.36469/9744","title":"Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism","year":2019,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Janssen Research and Development; Janssen Scientific Affairs","keywords":"Medicine; Pulmonary embolism; Confidence interval; Odds ratio; Pulmonary angiography; Internal medicine; Logistic regression; Cardiology","score_opus":0.012161005805151674,"score_gpt":0.305075553548598,"score_spread":0.29291454774344633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975211644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992581,0.00023885901,0.000048107144,0.00008773291,0.0000043699806,0.0000027697956,0.00020058393,0.000002117013,0.00015718359],"genre_scores_gemma":[0.999645,0.000054052834,0.000034333898,0.000012830571,0.00000731968,0.0000020590383,0.00021054602,5.6273143e-7,0.000033387194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974054,0.00006278079,0.000044410575,0.000039578204,0.000053788124,0.000058908172],"domain_scores_gemma":[0.9974674,0.00044088243,0.0014545645,0.000051174797,0.00020361104,0.0003823307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038322073,0.00019413169,0.00019240483,0.00043255396,0.00020559553,0.00050109235,0.000279404,0.00030114502,0.0016740137],"category_scores_gemma":[0.0031436114,0.00010984116,0.0002441518,0.0005517356,0.0001499649,0.00031532595,0.0003241783,0.0006127333,0.00015435321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002161937,0.0000070219353,0.99961734,0.0000028323955,0.000007988434,0.000013333529,0.0000062211375,0.000021554832,0.000020128708,0.0000043580276,0.000037986225,0.00023968206],"study_design_scores_gemma":[0.000003100634,0.000044115088,0.999323,0.000007639713,0.000010552169,0.00015262928,0.0000655177,0.00029454395,0.000020104635,0.000020959773,0.000056165558,0.0000017581783],"about_ca_topic_score_codex":0.003199433,"about_ca_topic_score_gemma":0.004200137,"teacher_disagreement_score":0.003199433,"about_ca_system_score_codex":0.0002822135,"about_ca_system_score_gemma":0.00035359565,"threshold_uncertainty_score":0.0063616037},"labels":[],"label_agreement":null},{"id":"W2976858013","doi":"10.36469/9682","title":"The Burden of Hypoxic Respiratory Failure in Preterm and Term/Near-term Infants in the United States 2011-2015","year":2019,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Neonatal Respiratory Health Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Medicine; Respiratory distress; Neonatal intensive care unit; Pediatrics; Odds ratio; Respiratory failure; Anesthesia; Internal medicine","score_opus":0.07789917381528427,"score_gpt":0.4370342213191848,"score_spread":0.3591350475039005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2976858013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992558,0.0015567833,0.00012717582,0.0002912858,0.000022842263,0.0000109686425,0.0047765924,0.000008432951,0.0006479411],"genre_scores_gemma":[0.99570304,0.00094335055,0.00012048786,0.00007788211,0.000027480164,0.000011416686,0.002969357,0.0000017751455,0.0001452157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943894,0.00010180629,0.00012832411,0.000112536465,0.00012757017,0.00009080332],"domain_scores_gemma":[0.998637,0.000098391974,0.0008105905,0.000044660523,0.00021613139,0.00019307877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065738667,0.00022411316,0.00021319123,0.00090967806,0.00028556422,0.0005191309,0.00050248706,0.00025861769,0.0007492208],"category_scores_gemma":[0.0018734041,0.00019313545,0.00048796434,0.0009904461,0.00020323698,0.00043617326,0.00097390974,0.0004833671,0.000107074455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001643383,0.000010117273,0.9975465,0.000027102893,0.00005799639,0.00005503308,0.000042076863,0.00010088922,0.000058206835,0.000035478934,0.0004229744,0.0016271999],"study_design_scores_gemma":[9.968892e-7,0.000018861097,0.9990281,0.00002911099,0.000021736358,0.0001606988,0.00017990325,0.0002245668,0.000032959462,0.000011628666,0.00028919382,0.0000022450383],"about_ca_topic_score_codex":0.04341822,"about_ca_topic_score_gemma":0.053572208,"teacher_disagreement_score":0.04341822,"about_ca_system_score_codex":0.0011031707,"about_ca_system_score_gemma":0.00093475817,"threshold_uncertainty_score":0.08633101},"labels":[],"label_agreement":null},{"id":"W2979536446","doi":"10.36469/9936","title":"Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care","year":2019,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Janssen Research and Development; Bayer","keywords":"Rivaroxaban; Medicine; Pulmonary embolism; Propensity score matching; Warfarin; Low molecular weight heparin; Anticoagulant; Internal medicine; Emergency medicine; Heparin; Atrial fibrillation","score_opus":0.037232915687053225,"score_gpt":0.4002287013889841,"score_spread":0.36299578570193086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979536446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99887127,0.00047522158,0.000032628934,0.00014802648,0.000009775209,0.000020744248,0.00019435627,8.698302e-7,0.00024707685],"genre_scores_gemma":[0.99940276,0.00010119212,0.00003276604,0.000051472318,0.000014803796,0.00001667009,0.0003560339,3.309762e-7,0.000024058236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857736,0.0006424917,0.00017419232,0.00020007773,0.00017626952,0.00022963583],"domain_scores_gemma":[0.9972446,0.0005952028,0.001336049,0.00007116987,0.00015926287,0.00059363025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014511269,0.00021414038,0.0006414763,0.00066965766,0.00033521652,0.0009130529,0.00038594272,0.0004426263,0.0011838131],"category_scores_gemma":[0.0067096036,0.00012543579,0.0010498276,0.00077812787,0.0003655304,0.0004895957,0.0006677398,0.00052586343,0.00008630043],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0107308775,0.0008747364,0.97587776,0.000115205454,0.0011337281,0.000108485816,0.000090587724,0.000984968,0.00017023145,0.00020491853,0.0006549583,0.009053573],"study_design_scores_gemma":[0.0015125561,0.005146621,0.9883859,0.00005743373,0.0004948083,0.00021844116,0.00026431913,0.0031034895,0.0001384807,0.00032193307,0.00033790458,0.000018213008],"about_ca_topic_score_codex":0.0033085619,"about_ca_topic_score_gemma":0.0032264462,"teacher_disagreement_score":0.0033085619,"about_ca_system_score_codex":0.0014960563,"about_ca_system_score_gemma":0.0007593922,"threshold_uncertainty_score":0.010854721},"labels":[],"label_agreement":null},{"id":"W2980833094","doi":"10.36469/9820","title":"A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma","year":2016,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Takeda Oncology; Sanofi; GlaxoSmithKline; Bristol-Myers Squibb","keywords":"Brentuximab vedotin; Medicine; Oncology; Internal medicine; Hodgkin lymphoma; Lymphoma","score_opus":0.09011777675505077,"score_gpt":0.4229909358078391,"score_spread":0.3328731590527883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980833094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9294314,0.038306948,0.015509257,0.0029029595,0.00020988245,0.0014286557,0.0039035042,0.00010925463,0.008198187],"genre_scores_gemma":[0.9948645,0.0020481306,0.0018119849,0.00016801173,0.000022879893,0.00016398316,0.00054449117,0.0000083711075,0.00036753385],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9964563,0.0028586355,0.00009808148,0.00018412371,0.00019939094,0.00020331543],"domain_scores_gemma":[0.9938059,0.005296545,0.00041210372,0.00009179304,0.0001687032,0.00022495893],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005611343,0.0014842949,0.0018543379,0.0013928104,0.00021088628,0.0017651359,0.0009826153,0.001219745,0.0033830595],"category_scores_gemma":[0.013018194,0.0007109054,0.00434285,0.0010346244,0.00049780344,0.0013241847,0.00088214397,0.0012451842,0.00015338883],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02530949,0.0007472584,0.013794797,0.0038756188,0.0087977005,0.00064504996,0.000098535216,0.8929099,0.0012253986,0.004543962,0.0016338499,0.046418495],"study_design_scores_gemma":[0.009064101,0.012725356,0.026325027,0.0019576328,0.013872129,0.00095293974,0.0004212689,0.92129546,0.0010373582,0.0072818487,0.004894421,0.0001724336],"about_ca_topic_score_codex":0.011963426,"about_ca_topic_score_gemma":0.0082008075,"teacher_disagreement_score":0.011963426,"about_ca_system_score_codex":0.0077173575,"about_ca_system_score_gemma":0.0025956947,"threshold_uncertainty_score":0.055993617},"labels":[],"label_agreement":null},{"id":"W2980909881","doi":"10.36469/9838","title":"The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need","year":2016,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); Université de Sherbrooke","funders":"","keywords":"Reimbursement; Incentive; Health technology; Compromise; Context (archaeology); Order (exchange); Risk analysis (engineering); Business; Actuarial science; Public economics; Medicine; Health care; Economics; Finance; Economic growth; Microeconomics; Political science","score_opus":0.4265158938132272,"score_gpt":0.5987527391384256,"score_spread":0.17223684532519845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980909881","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022389945,0.0049289973,0.7559285,0.037029017,0.0009291515,0.000763828,0.00053363695,0.00050281093,0.17699413],"genre_scores_gemma":[0.8402758,0.0043356773,0.13425672,0.003422526,0.0013299796,0.0012104627,0.000100835576,0.0001769836,0.0148910545],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9907177,0.004739209,0.0003593509,0.0015339338,0.001982556,0.0006671275],"domain_scores_gemma":[0.9589587,0.031957466,0.0035515067,0.0030293765,0.001990345,0.00051257416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016153047,0.0013595128,0.0014527439,0.003910066,0.001716256,0.008276164,0.0030395687,0.0071492675,0.013563196],"category_scores_gemma":[0.04663346,0.00078419165,0.0018821117,0.0021427956,0.012841073,0.011918878,0.003769007,0.004582639,0.0011271691],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020739664,0.000029564731,0.0004241656,0.00009179324,0.000014405938,0.00007266535,0.00008070929,0.0053817974,0.00017628413,0.98379636,0.0011689644,0.008742624],"study_design_scores_gemma":[0.000042392745,0.00010583698,0.000717032,0.00012432087,0.000048093934,0.0001839979,0.00011404464,0.03237396,0.0005396724,0.953486,0.01220885,0.00005582145],"about_ca_topic_score_codex":0.0016844182,"about_ca_topic_score_gemma":0.0013760587,"teacher_disagreement_score":0.016153047,"about_ca_system_score_codex":0.005983293,"about_ca_system_score_gemma":0.004668031,"threshold_uncertainty_score":0.08542651},"labels":[],"label_agreement":null},{"id":"W2981105730","doi":"10.36469/9841","title":"Treatment Patterns for Patients on Overactive Bladder Therapy: A Retrospective Statistical Analysis Using Canadian Claims Data","year":2016,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Government of Canada; University of Alberta","funders":"Health Canada; Astellas Pharma","keywords":"Discontinuation; Medicine; Overactive bladder; Medical prescription; Proportional hazards model; Internal medicine; Polypharmacy; Hazard ratio; Univariate analysis; Retrospective cohort study; Multivariate analysis; Emergency medicine; Pharmacology; Confidence interval; Alternative medicine","score_opus":0.21180798206610071,"score_gpt":0.49249442052290265,"score_spread":0.28068643845680197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981105730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95755154,0.0018472192,0.0006976803,0.00025194025,0.000014633554,0.00030702545,0.037860703,0.000053320975,0.0014160292],"genre_scores_gemma":[0.983165,0.00090726884,0.0007941304,0.00007021439,0.00001051094,0.00013974735,0.014676038,0.00001620086,0.00022084406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940667,0.00056684215,0.00090923894,0.0008787934,0.0028271005,0.00075128843],"domain_scores_gemma":[0.9825271,0.0026491554,0.0073668617,0.0011365887,0.005130945,0.0011892767],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051368857,0.0006257867,0.0009836584,0.0094751185,0.002034152,0.0019411304,0.0015654325,0.000579567,0.0019119377],"category_scores_gemma":[0.014960643,0.0006708231,0.0023387792,0.019764433,0.00075539586,0.00066352054,0.0014310878,0.0008870668,0.000254667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011556613,0.00001531237,0.99700576,0.00006650971,0.0001900993,0.000040510076,0.00015695048,0.00015585581,0.00003510432,0.000040458224,0.0004963818,0.0016814846],"study_design_scores_gemma":[0.000012622051,0.00003844381,0.99762005,0.000038779708,0.00011273367,0.00010064103,0.0002806004,0.00095132703,0.000036234953,0.000022217617,0.0007675118,0.000018852159],"about_ca_topic_score_codex":0.93976736,"about_ca_topic_score_gemma":0.883793,"teacher_disagreement_score":0.06023264,"about_ca_system_score_codex":0.017993134,"about_ca_system_score_gemma":0.023021773,"threshold_uncertainty_score":0.13054997},"labels":[],"label_agreement":null},{"id":"W2981122903","doi":"10.36469/9824","title":"Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain","year":2016,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rivaroxaban; Knee replacement; Antithrombotic; Arthroplasty; Observational study; Hip replacement; Enoxaparin sodium; Low molecular weight heparin; Randomized controlled trial; Clinical trial; Thrombosis; Surgery; Anesthesia; Internal medicine; Atrial fibrillation; Warfarin","score_opus":0.0769273760446206,"score_gpt":0.44422528613199874,"score_spread":0.3672979100873781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981122903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95912224,0.016226381,0.0032845952,0.0031847383,0.0001560635,0.00034698527,0.008692561,0.00007038279,0.008915956],"genre_scores_gemma":[0.9926645,0.0026165221,0.0010579013,0.00023962083,0.000027638416,0.00014103115,0.002538049,0.000011395651,0.0007032891],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9968899,0.0020315496,0.00015554075,0.00018683483,0.0002925317,0.00044360347],"domain_scores_gemma":[0.9947096,0.0024925147,0.0013118223,0.00016370388,0.0006725398,0.00064969616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053969263,0.0007967337,0.00075984397,0.002077914,0.00022089302,0.0020710179,0.00073270267,0.0009457055,0.002309083],"category_scores_gemma":[0.009079832,0.00036987566,0.0017213484,0.0020356101,0.00040448824,0.0007522764,0.0011514077,0.0007951243,0.00017363651],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016317,0.0015845149,0.31726992,0.002131951,0.0026136844,0.0012306672,0.00018669764,0.56202734,0.0008602022,0.008642532,0.010854849,0.07628065],"study_design_scores_gemma":[0.009005597,0.0063344766,0.5969841,0.0027388148,0.0043907105,0.0017146717,0.0021620893,0.33034217,0.0018503236,0.00795554,0.03626448,0.00025703487],"about_ca_topic_score_codex":0.05730135,"about_ca_topic_score_gemma":0.023460887,"teacher_disagreement_score":0.05730135,"about_ca_system_score_codex":0.010578027,"about_ca_system_score_gemma":0.006764258,"threshold_uncertainty_score":0.11393565},"labels":[],"label_agreement":null},{"id":"W2981126019","doi":"10.36469/9837","title":"Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective","year":2016,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Southlake Regional Health Center","funders":"Biosense Webster","keywords":"Medicine; Atrial fibrillation; Cost effectiveness; Quality-adjusted life year; Cohort; Catheter ablation; Cost-effectiveness analysis; Confidence interval; Cost–benefit analysis; Emergency medicine; Internal medicine; Demography","score_opus":0.22154609529089692,"score_gpt":0.4773155426121317,"score_spread":0.2557694473212348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981126019","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44011214,0.11040065,0.020240765,0.10309685,0.001067747,0.00097527914,0.03813547,0.00017988331,0.28579134],"genre_scores_gemma":[0.9699518,0.01735722,0.0054453583,0.001392224,0.00013083206,0.00008941844,0.0025793558,0.000027839713,0.0030260012],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9977196,0.00080632546,0.00008609183,0.00015809694,0.0007884993,0.00044134352],"domain_scores_gemma":[0.997242,0.0009880244,0.00022245925,0.000031870964,0.0011479864,0.00036761898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020985892,0.00089184963,0.0008099222,0.00241555,0.0012794945,0.0030194647,0.0013009432,0.001465147,0.0056076963],"category_scores_gemma":[0.00952761,0.0003501389,0.0018654019,0.0031206745,0.0007700418,0.00084308407,0.00067232974,0.0013460488,0.00020215778],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002259947,0.0002753767,0.051021744,0.0020904338,0.0026459051,0.00079360383,0.0004621964,0.6436388,0.0010664833,0.12614313,0.04813181,0.121470585],"study_design_scores_gemma":[0.0016970917,0.0007910079,0.103553854,0.0029822418,0.004642025,0.0011621675,0.0019487123,0.7494483,0.00095260376,0.04557505,0.08667281,0.000574122],"about_ca_topic_score_codex":0.96036273,"about_ca_topic_score_gemma":0.9555133,"teacher_disagreement_score":0.92000484,"about_ca_system_score_codex":0.07999517,"about_ca_system_score_gemma":0.07980183,"threshold_uncertainty_score":0.58040833},"labels":[],"label_agreement":null},{"id":"W2981257856","doi":"10.36469/9844","title":"The Direct Healthcare Expenditures of Prostate Cancer by Disease Severity: Evidence from US National Survey Data","year":2016,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bristol-Myers Squibb (Canada)","funders":"Bristol-Myers Squibb","keywords":"Medicine; Medical Expenditure Panel Survey; Diagnosis code; Prostate cancer; Chemotherapy; Cancer; Disease; Health care; Population; Internal medicine; Multivariate analysis; Indirect costs; Oncology; Health insurance; Environmental health","score_opus":0.2482978177145586,"score_gpt":0.44331870844347515,"score_spread":0.19502089072891654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981257856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9068139,0.055180587,0.0007254458,0.0036487503,0.00012138965,0.00008963413,0.028724821,0.000030186462,0.0046652784],"genre_scores_gemma":[0.9773093,0.012276436,0.0003304369,0.00033546932,0.00007656121,0.000032644468,0.009474167,0.000004934532,0.00016007527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973049,0.0012887466,0.00035780857,0.00019312193,0.0007127548,0.00014256156],"domain_scores_gemma":[0.98570466,0.0048772837,0.006832589,0.0004929129,0.0015853032,0.00050734205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034922014,0.0004020379,0.00042708067,0.0025679034,0.00016582852,0.0005453515,0.0005285305,0.0002741257,0.0014686916],"category_scores_gemma":[0.016013233,0.00027111173,0.0016136519,0.004655123,0.00026526925,0.0005411389,0.0008807422,0.00053573714,0.00013998951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011958764,0.000027294129,0.9858445,0.0004132616,0.0011492722,0.000017764829,0.000024806954,0.0005841984,0.000009197211,0.000088377165,0.0020420146,0.009679687],"study_design_scores_gemma":[0.000015461914,0.00004759399,0.99661225,0.0002716557,0.00050325703,0.000065377426,0.00005747357,0.00059422123,0.000022003871,0.00009445168,0.0017100341,0.0000062002705],"about_ca_topic_score_codex":0.025894182,"about_ca_topic_score_gemma":0.046034254,"teacher_disagreement_score":0.025894182,"about_ca_system_score_codex":0.0008198375,"about_ca_system_score_gemma":0.0009761275,"threshold_uncertainty_score":0.05148697},"labels":[],"label_agreement":null},{"id":"W3071800551","doi":"10.36469/jheor.2020.13687","title":"Sternal-Wound Infections following Coronary Artery Bypass Graft: Could Implementing Value-Based Purchasing be Beneficial?","year":2020,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Surgical site infection prevention","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Purchasing; Health care; Intervention (counseling); Total cost; Mortality rate; Emergency medicine; Environmental health; Business; Surgery; Operations management; Economic growth; Economics; Nursing","score_opus":0.12983970766872016,"score_gpt":0.44217910647190295,"score_spread":0.3123393988031828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3071800551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8886274,0.028991248,0.02443798,0.034858268,0.00020349455,0.0007016502,0.00092103396,0.00004489544,0.021214083],"genre_scores_gemma":[0.98715705,0.0053152964,0.006573544,0.00060757226,0.000036929592,0.000090437956,0.00010172985,0.0000042007714,0.00011325895],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9947465,0.004174662,0.0001939036,0.00016570672,0.00036729054,0.00035196933],"domain_scores_gemma":[0.97928065,0.01565729,0.0030074818,0.00027658974,0.0013228598,0.0004551203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009688304,0.00032179774,0.0004796441,0.0006004757,0.00027519147,0.0026901274,0.00068905245,0.0008053109,0.0022506337],"category_scores_gemma":[0.027227331,0.00024687083,0.0010447308,0.0011302205,0.00078367617,0.0019241221,0.0008970081,0.0009683832,0.000107403015],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015025026,0.0010139524,0.32233754,0.00975658,0.0018272443,0.0008987169,0.0017326452,0.16549627,0.0010724158,0.05296931,0.0048893015,0.43650353],"study_design_scores_gemma":[0.0010728182,0.0055899317,0.32318327,0.0317065,0.0037387349,0.0014172067,0.014910162,0.37267673,0.004662365,0.20149189,0.03925818,0.00029222714],"about_ca_topic_score_codex":0.005352113,"about_ca_topic_score_gemma":0.008610479,"teacher_disagreement_score":0.009688304,"about_ca_system_score_codex":0.0030499701,"about_ca_system_score_gemma":0.004701189,"threshold_uncertainty_score":0.051237226},"labels":[],"label_agreement":null},{"id":"W3125064772","doi":"10.36469/jheor.2021.18727","title":"A Systematic Literature Review and Indirect Treatment Comparison of Efficacy of Repository Corticotropin Injection versus Synthetic Adrenocorticotropic Hormone for Infantile Spasms","year":2021,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals","keywords":"Adrenocorticotropic hormone; Medicine; Psychology; Hormone; Internal medicine","score_opus":0.06527118050900231,"score_gpt":0.425321204746247,"score_spread":0.3600500242372447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125064772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045868284,0.9905434,0.00044149623,0.00026185068,0.00021949685,0.0020766964,0.001068015,0.000025177767,0.00077697815],"genre_scores_gemma":[0.09229739,0.89573216,0.0025679285,0.0013161455,0.00026170423,0.0063190046,0.0008999812,0.000023321683,0.00058235525],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9848948,0.006870809,0.0050104707,0.0010802977,0.001804338,0.0003393759],"domain_scores_gemma":[0.97257644,0.020373888,0.004597732,0.00033400126,0.0017807607,0.00033722268],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011349274,0.0020794065,0.016925232,0.010186001,0.0007853976,0.0030618662,0.0023687908,0.0025372284,0.009956074],"category_scores_gemma":[0.03778228,0.0010491052,0.0149732875,0.008533402,0.0012072502,0.002650197,0.0015308537,0.0016618605,0.0004929338],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015121984,0.000026033105,0.0004613915,0.944461,0.040185682,0.0000745392,0.000096836215,0.00012277605,0.00016173306,0.0001733062,0.00043187648,0.012292691],"study_design_scores_gemma":[0.004393628,0.0011424529,0.0038109669,0.509235,0.47190797,0.00029350733,0.00027393425,0.00023906965,0.00024131655,0.00045258095,0.007945702,0.00006382877],"about_ca_topic_score_codex":0.0062912074,"about_ca_topic_score_gemma":0.0154003855,"teacher_disagreement_score":0.016925232,"about_ca_system_score_codex":0.0054563372,"about_ca_system_score_gemma":0.008945463,"threshold_uncertainty_score":0.0600214},"labels":[],"label_agreement":null},{"id":"W3160231534","doi":"10.36469/jheor.2021.22978","title":"Determinants of COVID-19 Case Fatality Rate in the US: Spatial Analysis Over One Year of the Pandemic","year":2021,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Health disparities and outcomes","field":"Social Sciences","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Case fatality rate; Pandemic; Demography; Coronavirus disease 2019 (COVID-19); Index (typography); Geography; Medicine; Environmental health; Disease; Population; Infectious disease (medical specialty); Sociology","score_opus":0.1925171522508727,"score_gpt":0.5136866145523198,"score_spread":0.32116946230144705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3160231534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532384,0.00027159002,0.0006396655,0.00040576237,0.000010687712,0.000020131329,0.0025789735,0.000019914372,0.00072952546],"genre_scores_gemma":[0.99801755,0.000113250666,0.00022784705,0.000028271063,0.000005512429,0.000013883551,0.0014419403,0.00000472428,0.00014710266],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9993661,0.00021528821,0.000054460746,0.00015970279,0.000089779285,0.000114635135],"domain_scores_gemma":[0.9967423,0.0009412863,0.0010517429,0.00030180492,0.000653936,0.0003089697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015800678,0.0002602085,0.00027017604,0.0012870431,0.00045517206,0.00078705593,0.0006605752,0.00040777633,0.002055714],"category_scores_gemma":[0.0069328975,0.00020800285,0.0011041568,0.0021036433,0.00035955422,0.0007748595,0.0010526457,0.0006827693,0.00023399657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034288478,0.000025164989,0.99568594,0.000010361035,0.0000755772,0.00003580106,0.0001300091,0.0014609932,0.000038295802,0.00009962281,0.0005077418,0.0018962914],"study_design_scores_gemma":[0.000003261878,0.000038539092,0.99069375,0.000017185588,0.000041837455,0.000078638936,0.0010461723,0.00726632,0.000033983524,0.00020661773,0.00056438864,0.000009365373],"about_ca_topic_score_codex":0.17146578,"about_ca_topic_score_gemma":0.11953169,"teacher_disagreement_score":0.17146578,"about_ca_system_score_codex":0.0011285831,"about_ca_system_score_gemma":0.0012822212,"threshold_uncertainty_score":0.34093547},"labels":[],"label_agreement":null},{"id":"W34993257","doi":"10.36469/jheor.2021.29145","title":"近代自然科学与传统学术的现代转型―以章太炎、康有为、梁启超为例","year":2009,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.11727117413093903,"score_gpt":0.4804030909012495,"score_spread":0.3631319167703105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W34993257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83892286,0.0031451865,0.0007922807,0.0031320134,0.000062015046,0.0003312022,0.12444182,0.00008596202,0.029086608],"genre_scores_gemma":[0.95691067,0.0031986681,0.0013815617,0.0005897494,0.00003866161,0.00015910158,0.03165559,0.000014900587,0.0060510566],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99938,0.000041127503,0.000057320744,0.000061367995,0.00031418027,0.0001459932],"domain_scores_gemma":[0.9984471,0.00009429371,0.00065438607,0.000036923695,0.00052258186,0.0002446754],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00036740248,0.0002434015,0.00022571204,0.0015685756,0.0012598664,0.0009646266,0.00056992663,0.00020487381,0.0074813417],"category_scores_gemma":[0.002108648,0.00016144909,0.0004039478,0.004295183,0.0004588154,0.00031682057,0.0005979112,0.00027559948,0.00055858376],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063293264,0.000027010432,0.9624317,0.00034157105,0.00011231573,0.0001234559,0.00034885958,0.00035346486,0.00021950333,0.0004614185,0.017267136,0.018250257],"study_design_scores_gemma":[0.0000122984175,0.000022798535,0.9845471,0.0001807929,0.000051523704,0.00015923921,0.00072566414,0.00041307724,0.0001071707,0.00009713251,0.013672887,0.000010213127],"about_ca_topic_score_codex":0.9678,"about_ca_topic_score_gemma":0.98578763,"teacher_disagreement_score":0.99874014,"about_ca_system_score_codex":0.01857369,"about_ca_system_score_gemma":0.02181739,"threshold_uncertainty_score":0.13476217},"labels":[],"label_agreement":null},{"id":"W4200326001","doi":"10.36469/jheor.2021.29145","title":"Real-World Treatment Patterns, Survival, and Costs for Ovarian Cancer in Canada: A Retrospective Cohort Study Using Provincial Administrative Data","year":2021,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Sunnybrook Hospital; AstraZeneca (Canada)","funders":"","keywords":"Medicine; Cohort; Retrospective cohort study; Stage (stratigraphy); Cancer; Disease; Internal medicine; Cohort study; Ovarian cancer","score_opus":0.22097682867969046,"score_gpt":0.4915679570257415,"score_spread":0.27059112834605104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200326001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516864,0.00075701246,0.00029135597,0.00038782184,0.000014537571,0.00020776947,0.044792958,0.000020002319,0.0018422555],"genre_scores_gemma":[0.9838113,0.00059958006,0.00054484693,0.00012732277,0.0000073792444,0.00012564046,0.014219242,0.000010308201,0.00055443397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980552,0.00013969962,0.00022224692,0.00030022408,0.0007671234,0.00051544316],"domain_scores_gemma":[0.99438745,0.00030001134,0.0018053579,0.0003918393,0.0024283263,0.00068696396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012725488,0.0004258117,0.00056527974,0.0027975475,0.002600135,0.001545278,0.0014623696,0.00044391677,0.0017406241],"category_scores_gemma":[0.005129851,0.0006591119,0.0011407003,0.010077516,0.00069011125,0.0005416398,0.00127902,0.0007879302,0.00024983587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004744165,0.00001829281,0.99698895,0.000047023328,0.000088064284,0.000048377675,0.00024422418,0.00013777576,0.0000412422,0.0000751109,0.0012361056,0.0010273543],"study_design_scores_gemma":[0.0000116917,0.000015836742,0.9970489,0.000060159986,0.00005750802,0.000076768854,0.0007229844,0.0006067941,0.000034819786,0.000032581553,0.0013193856,0.000012465207],"about_ca_topic_score_codex":0.99233353,"about_ca_topic_score_gemma":0.9938922,"teacher_disagreement_score":0.9641029,"about_ca_system_score_codex":0.03589708,"about_ca_system_score_gemma":0.04096666,"threshold_uncertainty_score":0.26045275},"labels":[],"label_agreement":null},{"id":"W4214849882","doi":"10.36469/jheor.2022.31825","title":"Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"HIV-related health complications and treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Tenofovir alafenamide; Medicine; Body mass index; Regimen; Weight change; Internal medicine; Weight loss; Human immunodeficiency virus (HIV); Obesity; Viral load; Antiretroviral therapy; Immunology","score_opus":0.038216147784170304,"score_gpt":0.3711196666282715,"score_spread":0.3329035188441012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214849882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966067,0.00019584513,0.00013514828,0.00006878306,0.000008122821,0.000015973646,0.0028237102,0.000004701208,0.00014114444],"genre_scores_gemma":[0.9958222,0.00012580292,0.00035038296,0.000048534246,0.0000117194195,0.000040624884,0.0035356423,0.0000017088664,0.0000634497],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99845755,0.00079288735,0.00019265343,0.00029817357,0.00015310242,0.00010560032],"domain_scores_gemma":[0.9948695,0.0012709412,0.0027989093,0.00042304507,0.00031806834,0.0003196002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021345995,0.00028005394,0.0003602164,0.0009227475,0.00030560902,0.0006438847,0.00044337905,0.0004685127,0.000896086],"category_scores_gemma":[0.005730203,0.00031389584,0.0007050793,0.0017435007,0.00031240846,0.0006065481,0.0005788096,0.00059538265,0.0001989068],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027350558,0.00006190238,0.9980107,0.00002209948,0.00017684331,0.000038933587,0.000041829477,0.0002547926,0.00004744052,0.000025964739,0.00026520324,0.000780797],"study_design_scores_gemma":[0.000049397502,0.00034962082,0.99410915,0.000029956016,0.0001294825,0.00023694617,0.000350167,0.004065144,0.00008807922,0.00006552974,0.0005119307,0.000014584283],"about_ca_topic_score_codex":0.009969921,"about_ca_topic_score_gemma":0.010235314,"teacher_disagreement_score":0.009969921,"about_ca_system_score_codex":0.00068294635,"about_ca_system_score_gemma":0.00044973023,"threshold_uncertainty_score":0.01982379},"labels":[],"label_agreement":null},{"id":"W4289793462","doi":"10.36469/jheor.2022.36975","title":"Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation; International Business Machines Corporation","keywords":"Medicine; Health care; Pharmacy; Myeloid leukemia; Population; Emergency medicine; Incidence (geometry); Internal medicine; Family medicine; Environmental health","score_opus":0.1146702665762677,"score_gpt":0.41339451824372464,"score_spread":0.298724251667457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289793462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774789,0.002198654,0.00010759529,0.00075912545,0.0000165143,0.000030741165,0.018476848,0.000009888975,0.0009217017],"genre_scores_gemma":[0.9863122,0.0010394949,0.00016566791,0.00022818803,0.000032907385,0.000049633207,0.0120148985,0.0000033951733,0.00015359814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99926144,0.00016193335,0.0001884726,0.00015175426,0.00013786714,0.00009854331],"domain_scores_gemma":[0.997283,0.00022328457,0.0020162417,0.000069202535,0.00017408471,0.00023420226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079228496,0.00022636422,0.0002830809,0.0011597328,0.00028597537,0.0010094378,0.0003168541,0.00042395625,0.0016544957],"category_scores_gemma":[0.0021274246,0.00021479391,0.00055100146,0.0037082974,0.00024629247,0.0007332873,0.00066273025,0.00055396144,0.00025991147],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055615295,0.000028690234,0.9961481,0.0000321691,0.000078840276,0.00002779435,0.00005337597,0.00014191629,0.00004822232,0.00005584548,0.0012608989,0.002068663],"study_design_scores_gemma":[0.0000055977557,0.000022177423,0.99835026,0.000033648925,0.000016341739,0.00012819961,0.00022498853,0.0003759439,0.000023391478,0.00003714271,0.00077829923,0.000004067051],"about_ca_topic_score_codex":0.026701508,"about_ca_topic_score_gemma":0.02595117,"teacher_disagreement_score":0.026701508,"about_ca_system_score_codex":0.0013617858,"about_ca_system_score_gemma":0.00065821485,"threshold_uncertainty_score":0.05309218},"labels":[],"label_agreement":null},{"id":"W4289815058","doi":"10.36469/001c.36976","title":"Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Myeloid leukemia; Perspective (graphical); Medicine; Phase (matter); Intensive care medicine; Internal medicine; Chemistry; Computer science; Artificial intelligence","score_opus":0.06831243107343316,"score_gpt":0.4248905147898626,"score_spread":0.35657808371642946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289815058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9265616,0.015775837,0.00040387202,0.011328804,0.0001840436,0.00013419546,0.039907407,0.000016737977,0.005687529],"genre_scores_gemma":[0.98057806,0.0052441796,0.00031785938,0.0010745109,0.00020508554,0.000110279194,0.011963202,0.0000055818678,0.0005013487],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920964,0.00023007178,0.0001240155,0.00010043493,0.00018055631,0.00015523819],"domain_scores_gemma":[0.99802727,0.00021622839,0.0012935257,0.000030330139,0.00017618855,0.00025648976],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006535106,0.00033316217,0.00029878967,0.001307655,0.00030870896,0.0013058821,0.000396797,0.0005339745,0.002958541],"category_scores_gemma":[0.0025786357,0.00021955548,0.00096230564,0.003915197,0.000235013,0.00086034794,0.00076860486,0.00089823623,0.00015995966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014047364,0.000098405915,0.97061557,0.00018212773,0.00036467516,0.00010270373,0.00012411969,0.0015531364,0.00008969588,0.0014334065,0.012449038,0.01284659],"study_design_scores_gemma":[0.000024604955,0.00006490999,0.99041,0.00022396457,0.00010502876,0.00025561877,0.00061686843,0.002687056,0.000051086274,0.00040824572,0.0051411656,0.0000114520835],"about_ca_topic_score_codex":0.050321396,"about_ca_topic_score_gemma":0.052673854,"teacher_disagreement_score":0.050321396,"about_ca_system_score_codex":0.003709543,"about_ca_system_score_gemma":0.0014263925,"threshold_uncertainty_score":0.100057006},"labels":[],"label_agreement":null},{"id":"W4289856100","doi":"10.36469/001c.36975","title":"Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation; International Business Machines Corporation","keywords":"Medicine; Health care; Myeloid leukemia; Pharmacy; Population; Incidence (geometry); Emergency medicine; Internal medicine; Family medicine; Environmental health","score_opus":0.1146702665762677,"score_gpt":0.41339451824372464,"score_spread":0.298724251667457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289856100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665247,0.0038244764,0.00015204102,0.0011065719,0.00002582057,0.000040788535,0.027018558,0.000012662117,0.0012944115],"genre_scores_gemma":[0.98225856,0.0016298892,0.00022663314,0.0002908213,0.000050483934,0.00006370451,0.015290979,0.0000040394057,0.000184859],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992107,0.00016915658,0.00021084123,0.00016091758,0.00014075573,0.00010750821],"domain_scores_gemma":[0.9972408,0.00023271295,0.002055943,0.00006438645,0.00017306628,0.00023314166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073990854,0.00024070161,0.00028520208,0.0013626056,0.00028522845,0.0011315688,0.00030457292,0.00041118098,0.001818955],"category_scores_gemma":[0.0023103368,0.00021107135,0.00058741786,0.0043348903,0.00024822418,0.0007846562,0.0006941113,0.00055747,0.00025747097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000052016378,0.000029177401,0.9950046,0.000044597404,0.00009339841,0.000030415167,0.000056313158,0.00017320465,0.000046222514,0.00009321084,0.0016133297,0.0027634636],"study_design_scores_gemma":[0.0000057011443,0.000021833263,0.9978992,0.000046285328,0.000019376932,0.00014214446,0.0002548426,0.00044251315,0.000024209408,0.000061449166,0.0010777613,0.000004773507],"about_ca_topic_score_codex":0.027085017,"about_ca_topic_score_gemma":0.02693811,"teacher_disagreement_score":0.027085017,"about_ca_system_score_codex":0.0014616888,"about_ca_system_score_gemma":0.00066242437,"threshold_uncertainty_score":0.053854704},"labels":[],"label_agreement":null},{"id":"W4289856656","doi":"10.36469/jheor.2022.36976","title":"Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective","year":2022,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Discontinuation; Dasatinib; Nilotinib; Internal medicine; Myeloid leukemia; Imatinib; Bosutinib; Pediatrics","score_opus":0.06831243107343316,"score_gpt":0.4248905147898626,"score_spread":0.35657808371642946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289856656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9374285,0.01168118,0.00032678718,0.009340159,0.00015147422,0.00011921956,0.03633361,0.000013982586,0.004605132],"genre_scores_gemma":[0.98175645,0.0040462026,0.0002645842,0.00092691847,0.0001690728,0.00010059316,0.012265384,0.00000510918,0.00046565646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991829,0.0002361931,0.00012632225,0.00010610328,0.00018970814,0.00015873248],"domain_scores_gemma":[0.99788827,0.00022633371,0.0014028312,0.00003356293,0.00018035604,0.00026863572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007513547,0.0003521988,0.00031552083,0.00130595,0.00031668137,0.0012951911,0.00044299226,0.00059084216,0.0029886758],"category_scores_gemma":[0.0025822523,0.00023676817,0.0010407903,0.0039961785,0.00025172453,0.00090220204,0.0007855581,0.0009851758,0.00017032915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013872645,0.00010040091,0.97545505,0.00015866781,0.00035437237,0.0000948541,0.000117612835,0.0015052446,0.00007959441,0.001095068,0.011304678,0.009595794],"study_design_scores_gemma":[0.000024694358,0.00006308716,0.9914581,0.00019784587,0.00009867434,0.00024018432,0.00056989206,0.002739262,0.000047652036,0.00033005007,0.0042198775,0.000010613823],"about_ca_topic_score_codex":0.052820794,"about_ca_topic_score_gemma":0.052610174,"teacher_disagreement_score":0.052820794,"about_ca_system_score_codex":0.0037937271,"about_ca_system_score_gemma":0.0015157091,"threshold_uncertainty_score":0.10502672},"labels":[],"label_agreement":null},{"id":"W4323038398","doi":"10.36469/001c.68191","title":"Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States","year":2023,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"GERD; Medicine; Cohort; Dysplasia; Barrett's esophagus; Esophagus; Internal medicine; Disease; Gastroenterology; Health care; Reflux; Adenocarcinoma; Cancer","score_opus":0.0475957058017199,"score_gpt":0.3743526500852333,"score_spread":0.3267569442835134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323038398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274534,0.0013312573,0.00005197643,0.00046033508,0.000018377954,0.000016723234,0.0042563826,0.0000054584475,0.0011142372],"genre_scores_gemma":[0.99678135,0.00047528968,0.0000807791,0.00015451263,0.000024760031,0.000017702925,0.002373255,0.0000011829596,0.000091260925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99935883,0.00015972278,0.00014054294,0.00008941208,0.00012401331,0.00012749583],"domain_scores_gemma":[0.9987068,0.00014560253,0.00074601587,0.000029266339,0.000107429,0.00026491308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003745297,0.000228712,0.00027913426,0.0011679588,0.00034535475,0.0006861109,0.0003004622,0.00031091063,0.001263962],"category_scores_gemma":[0.001995761,0.00016023933,0.0006038161,0.0021920446,0.00023123885,0.0004985012,0.0006201953,0.00048038925,0.00011636533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035378544,0.00003665982,0.997241,0.000020236983,0.000085342064,0.000055773937,0.000027535922,0.00022362465,0.000025377902,0.00006357289,0.00066510245,0.0015202852],"study_design_scores_gemma":[0.000008790171,0.0000447242,0.99814,0.000033591856,0.000041520576,0.00018307618,0.00021675724,0.00078185234,0.000023493942,0.00006712252,0.00045426207,0.000004773585],"about_ca_topic_score_codex":0.033066735,"about_ca_topic_score_gemma":0.03703695,"teacher_disagreement_score":0.033066735,"about_ca_system_score_codex":0.0012291658,"about_ca_system_score_gemma":0.00078501855,"threshold_uncertainty_score":0.06574857},"labels":[],"label_agreement":null},{"id":"W4323064029","doi":"10.36469/jheor.2023.68191","title":"Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett’s Esophagus, and Barrett’s Esophagus-Related Neoplasia in the United States","year":2023,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"GERD; Medicine; Cohort; Dysplasia; Esophagus; Barrett's esophagus; Internal medicine; Disease; Gastroenterology; Health care; Reflux; Adenocarcinoma; Cancer","score_opus":0.0475957058017199,"score_gpt":0.3743526500852333,"score_spread":0.3267569442835134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323064029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99406236,0.0010216244,0.000044986275,0.00040575876,0.000014648245,0.000013952216,0.003484548,0.000004808981,0.0009472138],"genre_scores_gemma":[0.9971048,0.00037329766,0.000070633796,0.00013633094,0.000018751307,0.000014943203,0.002194256,0.0000011314233,0.000085783984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99939,0.00015821023,0.00013267697,0.00008050182,0.00012628664,0.000112320915],"domain_scores_gemma":[0.99867994,0.00014633905,0.000784972,0.000032148328,0.000111082736,0.00024543927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004191084,0.00022962579,0.0002616175,0.0010836419,0.00035163463,0.000641987,0.00031570377,0.00032741195,0.0011978522],"category_scores_gemma":[0.001960729,0.00017451555,0.000569581,0.0020127199,0.00022737871,0.00049695687,0.0005951906,0.0005205974,0.00012353373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003690524,0.00003529181,0.9976446,0.000016976564,0.0000812011,0.000051354284,0.000027375501,0.000186954,0.000024729392,0.000048704376,0.00060424383,0.0012416585],"study_design_scores_gemma":[0.000008348989,0.000043104257,0.9983656,0.000029521363,0.00003711959,0.00017083708,0.00020209333,0.00069151155,0.000021366053,0.00005231866,0.00037398215,0.0000041806516],"about_ca_topic_score_codex":0.031173103,"about_ca_topic_score_gemma":0.03610044,"teacher_disagreement_score":0.031173103,"about_ca_system_score_codex":0.0012009135,"about_ca_system_score_gemma":0.00077979953,"threshold_uncertainty_score":0.061983347},"labels":[],"label_agreement":null},{"id":"W4323765291","doi":"10.36469/jheor.2019.9744","title":"Predictors of Hospital Length of Stay among Patients with Low-risk Pulmonary Embolism","year":2019,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Janssen Scientific Affairs","keywords":"Medicine; Pulmonary embolism; Confidence interval; Odds ratio; Pulmonary angiography; Internal medicine; Logistic regression; Cardiology","score_opus":0.012161005805151674,"score_gpt":0.305075553548598,"score_spread":0.29291454774344633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323765291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99924797,0.00023696908,0.000049326864,0.00009108985,0.000004480603,0.0000028145605,0.00020339136,0.0000021424223,0.00016164311],"genre_scores_gemma":[0.99963784,0.000055026783,0.00003582352,0.000013170431,0.0000074401864,0.0000021159822,0.00021372369,5.7884773e-7,0.00003433938],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9997409,0.00006163619,0.000044651257,0.00003919363,0.000054028747,0.000059604175],"domain_scores_gemma":[0.9974396,0.00044911366,0.0014650095,0.000050803275,0.00020841084,0.0003870326],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038149804,0.00019486052,0.00019359268,0.0004337415,0.00020822292,0.0005009858,0.0002789462,0.00030143114,0.0017048726],"category_scores_gemma":[0.0032075911,0.00011008138,0.00024693555,0.0005515994,0.00014775193,0.00031842853,0.00033072953,0.00061809423,0.00015972814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002217333,0.000007094305,0.9996074,0.0000028839672,0.000007907313,0.0000139702815,0.000006400198,0.000022190023,0.000020239826,0.0000044371664,0.000039249284,0.00024614087],"study_design_scores_gemma":[0.000003060922,0.000044925517,0.99929667,0.000007973086,0.0000106756615,0.00015804193,0.00006896438,0.00030811044,0.00002036063,0.000021718926,0.000057702728,0.0000018146332],"about_ca_topic_score_codex":0.0031568692,"about_ca_topic_score_gemma":0.004123289,"teacher_disagreement_score":0.0031568692,"about_ca_system_score_codex":0.00027858128,"about_ca_system_score_gemma":0.00035623054,"threshold_uncertainty_score":0.006276965},"labels":[],"label_agreement":null},{"id":"W4401698523","doi":"10.36469/jheor.2024.121233","title":"Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting","year":2024,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Prostate cancer; Internal medicine; Urology; Androgen deprivation therapy; Bicalutamide; Cohort; Oncology; Cancer; Androgen receptor","score_opus":0.0954274413607885,"score_gpt":0.4685944567940695,"score_spread":0.373167015433281,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401698523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9991499,0.00010202291,0.0000372196,0.000058874157,0.0000022033626,0.0000069741477,0.00047261803,0.000002120457,0.0001681605],"genre_scores_gemma":[0.9993825,0.000061098355,0.000053930267,0.000031791315,0.000005398633,0.00000862802,0.00042478487,9.87918e-7,0.000030959953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990164,0.0003093564,0.00012861234,0.00021350244,0.00017289212,0.00015915117],"domain_scores_gemma":[0.99487877,0.00053408917,0.0036169486,0.00015724152,0.00028503162,0.0005280378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009459204,0.00016140816,0.00026581838,0.0009964249,0.0005478348,0.00067169766,0.0004244399,0.0003644146,0.0009641691],"category_scores_gemma":[0.0030861367,0.0002365617,0.00037442206,0.0013935401,0.00037049095,0.0006367008,0.00056105584,0.00055964367,0.0001404611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003121017,0.00001844557,0.99942786,0.000003737451,0.000021393927,0.000017351324,0.000055491364,0.000020490394,0.000026758507,0.000006695243,0.00004502192,0.0003255215],"study_design_scores_gemma":[0.0000060748157,0.00008206197,0.99893004,0.000007393195,0.000015566558,0.00017687916,0.00039793065,0.00018728686,0.000040321323,0.000016020262,0.00013566269,0.000004830511],"about_ca_topic_score_codex":0.013053118,"about_ca_topic_score_gemma":0.01814158,"teacher_disagreement_score":0.013053118,"about_ca_system_score_codex":0.0008086301,"about_ca_system_score_gemma":0.0007385992,"threshold_uncertainty_score":0.025954306},"labels":[],"label_agreement":null},{"id":"W4403810575","doi":"10.36469/001c.124208","title":"Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Bladder cancer; Context (archaeology); Maintenance therapy; Carcinoma in situ; Internal medicine; Guideline; Oncology; Cancer; Urology; Surgery; Chemotherapy; Pathology","score_opus":0.09136423934102175,"score_gpt":0.4284052855017772,"score_spread":0.3370410461607555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403810575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839828,0.0038799143,0.00064333563,0.0046355366,0.000089793815,0.0001494827,0.0022230195,0.000036597812,0.0043594562],"genre_scores_gemma":[0.99700624,0.000647789,0.0006635601,0.00055806694,0.00003640459,0.00006163472,0.00088984554,0.000004443679,0.0001320885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974777,0.0010281937,0.00056117505,0.00021986621,0.00052530423,0.00018781528],"domain_scores_gemma":[0.9913372,0.0023381023,0.0046477434,0.00020996552,0.0009263261,0.0005407133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020899542,0.000083764244,0.00032626712,0.00062390126,0.00027122005,0.000564396,0.00038993548,0.00040953545,0.00078309025],"category_scores_gemma":[0.018814476,0.00009362377,0.00039388073,0.0014086249,0.00012287326,0.0003447917,0.00032969727,0.00063334417,0.00007793938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011787804,0.00011630512,0.97358954,0.00010428605,0.000105058396,0.000050399925,0.00020256329,0.0002279525,0.00006511179,0.00007416474,0.0027650297,0.022581762],"study_design_scores_gemma":[0.000047938414,0.00018877267,0.9938008,0.00026146078,0.00009430118,0.00016977079,0.00048684186,0.0020772452,0.00014127677,0.0001103697,0.0026123237,0.000008977131],"about_ca_topic_score_codex":0.02013092,"about_ca_topic_score_gemma":0.0314848,"teacher_disagreement_score":0.02013092,"about_ca_system_score_codex":0.00084366987,"about_ca_system_score_gemma":0.001695247,"threshold_uncertainty_score":0.0400275},"labels":[],"label_agreement":null},{"id":"W4407240390","doi":"10.36469/jheor.2025.127820","title":"Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Psoriasis; Retrospective cohort study; Medicine; Drug; Cohort; Internal medicine; Dermatology; Pharmacology","score_opus":0.03267356853526875,"score_gpt":0.36064143991909187,"score_spread":0.3279678713838231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407240390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976259,0.00042781848,0.000112503316,0.000045458266,0.0000079514475,0.000080846075,0.0012529091,0.0000038774992,0.00044275305],"genre_scores_gemma":[0.9986759,0.00019979448,0.00010772215,0.00006139199,0.000010954314,0.00004149338,0.00078233145,0.0000024901938,0.00011801271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988059,0.00014050025,0.00012465879,0.00036478584,0.0002913205,0.0002728434],"domain_scores_gemma":[0.99819285,0.00019691687,0.00076002727,0.0002043819,0.00032350232,0.0003222737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088373484,0.0003888156,0.0005832254,0.0013867498,0.0013517187,0.0009150534,0.0006591725,0.00048669058,0.0020541227],"category_scores_gemma":[0.002012994,0.00050332403,0.00063217606,0.0030789727,0.0005299364,0.0005699407,0.0006396104,0.0007174303,0.0002765423],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008136879,0.000032287313,0.9989643,0.000014897338,0.000066940374,0.00009239402,0.00008114235,0.0000122871,0.00006661616,0.000011898995,0.0001482447,0.0004276595],"study_design_scores_gemma":[0.000018798937,0.00009812033,0.99867517,0.00001839994,0.000071870556,0.00036324214,0.00030375962,0.00010679401,0.000021359047,0.000013730531,0.00030169307,0.0000070211936],"about_ca_topic_score_codex":0.17398416,"about_ca_topic_score_gemma":0.18182367,"teacher_disagreement_score":0.17398416,"about_ca_system_score_codex":0.0017679646,"about_ca_system_score_gemma":0.0021460534,"threshold_uncertainty_score":0.3459429},"labels":[],"label_agreement":null},{"id":"W4407253168","doi":"10.36469/001c.127820","title":"Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"","keywords":"Medicine; Psoriasis; Retrospective cohort study; Cohort; Medical prescription; Prescription drug; Family medicine; Internal medicine; Dermatology; Pharmacology","score_opus":0.03267356853526875,"score_gpt":0.36064143991909187,"score_spread":0.3279678713838231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407253168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99707687,0.0006021813,0.00014333073,0.000052286017,0.000009916405,0.00010745608,0.001487778,0.0000048082748,0.00051534123],"genre_scores_gemma":[0.99845874,0.00026128735,0.00013117757,0.000067385474,0.000013808252,0.00005236278,0.00088561716,0.0000026770813,0.00012692566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99879324,0.0001442435,0.00013371499,0.00036743245,0.000284419,0.00027690647],"domain_scores_gemma":[0.9982736,0.00019612799,0.0007021363,0.00018881277,0.0003145432,0.00032479817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008524404,0.00039800265,0.000612467,0.0014620794,0.0012891833,0.00088304887,0.00066763064,0.000486108,0.002212122],"category_scores_gemma":[0.0020220918,0.0005033896,0.0006478149,0.0033110518,0.0004983007,0.0005663292,0.0006202012,0.00069366855,0.00028582843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080126876,0.00003468533,0.9987924,0.000019935173,0.000077185905,0.00010672336,0.00008362318,0.000014327716,0.00007079148,0.000013732823,0.00016497447,0.0005413924],"study_design_scores_gemma":[0.000020048281,0.00009486015,0.99860436,0.00002197344,0.00008253218,0.00037978232,0.00028341135,0.00011440714,0.00002177547,0.00001578098,0.00035319233,0.00000775774],"about_ca_topic_score_codex":0.16894042,"about_ca_topic_score_gemma":0.17931367,"teacher_disagreement_score":0.16894042,"about_ca_system_score_codex":0.0017060075,"about_ca_system_score_gemma":0.0019821743,"threshold_uncertainty_score":0.33591413},"labels":[],"label_agreement":null},{"id":"W4412855801","doi":"10.36469/001c.141170","title":"Prostate-Specific Antigen Reduction After Androgen Receptor Pathway Inhibitor Initiation: Real-World Comparison of Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Enzalutamide; Prostate cancer; Hazard ratio; Abiraterone acetate; Oncology; Urology; Prostate-specific antigen; Internal medicine; Confidence interval; Cancer; Prostate; Androgen deprivation therapy; Androgen receptor","score_opus":0.0523072026035814,"score_gpt":0.41339692291669683,"score_spread":0.3610897203131154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412855801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992055,0.00014621291,0.00005320127,0.000015894655,0.0000054464017,0.00001822392,0.0004353678,0.0000016250735,0.00011837047],"genre_scores_gemma":[0.9990447,0.000048396636,0.000038427075,0.000011788219,0.0000074831714,0.000016911661,0.00078909786,0.0000010589695,0.000042181673],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855274,0.0005168419,0.00016635726,0.00041315935,0.0001597991,0.0001910514],"domain_scores_gemma":[0.9973797,0.00043205422,0.0014367895,0.00018663345,0.0001493274,0.0004154793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015984634,0.00045406978,0.0005205609,0.00088825973,0.0003071782,0.0008512581,0.00071167917,0.0005614373,0.0011690052],"category_scores_gemma":[0.00356386,0.00033233615,0.0012397305,0.0010419581,0.0003986377,0.0008219691,0.00095852965,0.0005782389,0.00019631999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027727678,0.00013449126,0.99446857,0.000029110057,0.00059677777,0.000034387744,0.000088641194,0.00021082429,0.00014889835,0.000031559364,0.000106151354,0.0013777796],"study_design_scores_gemma":[0.00017675244,0.0008063035,0.9971726,0.000010536423,0.00020918749,0.00013020943,0.00020316083,0.0009319632,0.00007843013,0.00005434862,0.00021268547,0.000013880981],"about_ca_topic_score_codex":0.006077487,"about_ca_topic_score_gemma":0.006978171,"teacher_disagreement_score":0.006077487,"about_ca_system_score_codex":0.0007344658,"about_ca_system_score_gemma":0.0004557988,"threshold_uncertainty_score":0.012084246},"labels":[],"label_agreement":null},{"id":"W4413824545","doi":"10.36469/001c.142771","title":"Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Osimertinib; Medicine; Lung cancer; Oncology; Internal medicine; non-small cell lung cancer (NSCLC); Immunotherapy; Chemotherapy; Health care; Epidermal growth factor receptor; Cancer; Erlotinib","score_opus":0.0543748553438399,"score_gpt":0.444466954937541,"score_spread":0.3900920995937011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413824545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916304,0.0003546676,0.000042200383,0.00010641825,0.0000028487962,0.000018789631,0.0072612623,0.0000031375184,0.0005803206],"genre_scores_gemma":[0.9944614,0.00027587937,0.00008389766,0.00006187176,0.000010331154,0.00004709299,0.0048972094,0.0000015536692,0.00016085792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99929225,0.00018999235,0.00017546117,0.00011973483,0.000107207365,0.00011528433],"domain_scores_gemma":[0.99830794,0.00035711995,0.0009952397,0.00003710442,0.00010324295,0.00019924736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040627227,0.00021051825,0.00031148293,0.0014641115,0.00029191587,0.000753084,0.00035998828,0.00037820375,0.0023287006],"category_scores_gemma":[0.0023490854,0.00015987488,0.0006648831,0.0033081938,0.00016945001,0.0007195614,0.0004886278,0.00036321505,0.000259641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001389969,0.000059876937,0.9974777,0.000025303465,0.00009152346,0.0000534359,0.0000484466,0.00031989644,0.00002979044,0.000042807384,0.00039762654,0.0013145965],"study_design_scores_gemma":[0.000016496168,0.00009860317,0.9975255,0.000022126707,0.000038909613,0.00015664908,0.00032141665,0.0012495684,0.000040704927,0.00006077378,0.00046170232,0.000007555485],"about_ca_topic_score_codex":0.017673273,"about_ca_topic_score_gemma":0.017813139,"teacher_disagreement_score":0.017673273,"about_ca_system_score_codex":0.0009722091,"about_ca_system_score_gemma":0.00050714565,"threshold_uncertainty_score":0.035140812},"labels":[],"label_agreement":null},{"id":"W7117448944","doi":"10.36469/001c.151273","title":"Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate","year":2025,"lang":"en","type":"article","venue":"Journal of health economics and outcomes research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Abiraterone acetate; Prostate cancer; Abiraterone; Prostate-specific antigen; Antiandrogen; Clinical trial","score_opus":0.11931529318118678,"score_gpt":0.46019572109938683,"score_spread":0.34088042791820006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117448944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9993777,0.00016148027,0.00004326721,0.000017890583,0.0000028531558,0.00000662544,0.00022997007,0.0000014687963,0.00015851561],"genre_scores_gemma":[0.99942636,0.0000676681,0.000038991828,0.000022212931,0.00000694517,0.000008665259,0.00036000964,0.000001346032,0.00006796904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99938977,0.00020268977,0.0000480393,0.00014635567,0.00010975665,0.00010339495],"domain_scores_gemma":[0.9978694,0.00045260208,0.0011968202,0.00007648988,0.00013389716,0.00027080826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009960814,0.00019857385,0.00037640712,0.0005643621,0.0002287541,0.0004249642,0.00029522667,0.00027137445,0.0009630875],"category_scores_gemma":[0.002836851,0.00015172442,0.0006061104,0.0005474245,0.000168235,0.00030952797,0.00031132915,0.00042582836,0.00012600896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005220274,0.00013560841,0.9887284,0.000028018292,0.00037813262,0.000046668505,0.00010885972,0.0002480926,0.0008409353,0.000041138766,0.00010686195,0.004116891],"study_design_scores_gemma":[0.0001372199,0.0014774298,0.9966953,0.0000099509325,0.00019890994,0.00016327795,0.0001248426,0.0005058101,0.00029323957,0.00004983991,0.00033803983,0.0000061709484],"about_ca_topic_score_codex":0.0031210333,"about_ca_topic_score_gemma":0.003439774,"teacher_disagreement_score":0.0031210333,"about_ca_system_score_codex":0.00050179067,"about_ca_system_score_gemma":0.00035165512,"threshold_uncertainty_score":0.006205678},"labels":[],"label_agreement":null}]}